| Quantifying the chemical beauty of drugs GR Bickerton, GV Paolini, J Besnard, S Muresan, AL Hopkins Nature chemistry 4 (2), 90-98, 2012 | 2093 | 2012 |
| Automated design of ligands to polypharmacological profiles J Besnard, GF Ruda, V Setola, K Abecassis, RM Rodriguiz, XP Huang, ... Nature 492 (7428), 215-220, 2012 | 891 | 2012 |
| Screening for GPCR ligands using surface plasmon resonance I Navratilova, J Besnard, AL Hopkins ACS medicinal chemistry letters 2 (7), 549-554, 2011 | 102 | 2011 |
| The joint european compound library: Boosting precompetitive research J Besnard, PS Jones, AL Hopkins, AD Pannifer Drug discovery today 20 (2), 181-186, 2015 | 83 | 2015 |
| Discovery of β2 adrenergic receptor ligands using biosensor fragment screening of tagged wild-type receptor T Aristotelous, S Ahn, AK Shukla, S Gawron, MF Sassano, AW Kahsai, ... ACS Medicinal Chemistry Letters 4 (10), 1005-1010, 2013 | 79 | 2013 |
| Quantifying the chemical beauty of drugs. Nat Chem 4: 90–98 GR Bickerton, GV Paolini, J Besnard, S Muresan, AL Hopkins, ... | 43 | 2012 |
| Application of RNAi to genomic drug target validation in schistosomes A Guidi, NR Mansour, RA Paveley, IM Carruthers, J Besnard, AL Hopkins, ... PLoS neglected tropical diseases 9 (5), e0003801, 2015 | 41 | 2015 |
| Multi-task learning with a natural metric for quantitative structure activity relationship learning N Sadawi, I Olier, J Vanschoren, JN Van Rijn, J Besnard, R Bickerton, ... Journal of Cheminformatics 11 (1), 1-13, 2019 | 27 | 2019 |
| Identification of a novel non-brain penetrant A2a R inhibitor and proof-of-concept of CD73 and A2a R/CD73 small-molecule inhibitors for cancer immunotherapy A HEK | 4 | 2018 |
| AI-driven discovery and profiling of GTAEXS-617, a selective and highly potent inhibitor of CDK7 J Besnard, J Joseph, H Bai, RA Paveley, T Wang, OR Barbeau, XH Gu, ... Cancer Research 82 (12_Supplement), 3930-3930, 2022 | 3 | 2022 |
| Condensed lactam derivative H Yoshinaga, Y Ikuma, J Ikeda, S Adachi, H Mitsunuma, Y Aihara, ... US Patent 10,745,401, 2020 | 3 | 2020 |
| De Novo Design of Ligands against Multitarget Profiles J Besnard, AL Hopkins De Novo Molecular Design, 287-309, 2013 | 3 | 2013 |
| Design of molecules AL Hopkins, J Besnard US Patent App. 13/510,599, 2012 | 3 | 2012 |
| 2, 6-disubstituted pyridine derivative H Yoshinaga, H Uemachi, T Ohno, J Besnard US Patent 10,800,755, 2020 | 2 | 2020 |
| Substituted lactams showing serotonin 5-HT receptor activity H Yoshinaga, Y Ikuma, J Ikeda, S Adachi, H Mitsunuma, Y Aihara, ... US Patent 11,466,007, 2022 | 1 | 2022 |
| 2, 6-Disubstituted pyridine derivative H Yoshinaga, H UEMACHI, T Ohno, J Besnard | 1 | 2020 |
| EVOEXS21546 is a novel non-brain penetrant A2AR inhibitor for cancer immunotherapy with accelerated drug development P Fons, A Bell, M Esquerre, S Versluys, F Bertrand, I Hopkins-Navratilova, ... Cancer Research 79 (13_Supplement), 519-519, 2019 | 1 | 2019 |
| Design of molecules AL Hopkins, J Besnard US Patent App. 14/986,516, 2016 | 1 | 2016 |
| Design of molecules A Hopkins, J Besnard | 1 | 2011 |
| AMIDOPYRIMIDONE DERIVATIVES AS Bell, J Besnard, AR Bradley, L Green, W Haap, B Kocer, A Kuglstatter, ... US Patent App. 18/654,989, 2024 | | 2024 |
Richard BickertonExscientiaVerified email at exscientia.co.uk